Hims & Hers Health Inc. (NYSE:HIMS) shares edged lower in Tuesday’s premarket session.
The company recently broadened its GLP-1 offerings and disclosed a planned share sale by its chief financial officer.
A recent filing showed Chief Financial Officer Oluyemi Okupe plans to sell nearly $5 million in stock.
The filing comes after Hims & Hers expanded into Novo Nordisk (NYSE:NVO) GLP-1 treatments.
Expansion Into GLP-1 Treatments
Hims & Hers Health recently broadened access to several GLP-1 drugs from Novo Nordisk.
The lineup includes Wegovy injections in multiple strengths. The company also plans to add a 7.2 mg dose soon.
Patients can also access oral GLP-1 options across several dosage levels. Pricing starts at $149 per month.
Providers will determine eligibility based on clinical assessments. Some patients may achieve meaningful weight loss through these treatments.
Wegovy Pill And Broader Access
The platform now includes the newly launched Wegovy pill. It is currently the only FDA-approved oral GLP-1 option for weight management.
The move aims to meet rising demand for convenient obesity treatments. The company seeks to streamline access through its digital platform.
Hims & Hers Technical Analysis
At $20.27, the stock is trading 8.4% below its 20-day simple moving average (SMA) of $22.15, suggesting short-term weakness. It is also 28% below its 100-day SMA of …
This post was originally published here